Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 110, Issue 4, Pages 512-516Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-019-02665-3
Keywords
Acute myeloid leukemia; NUP98; NSD1; FLT3; ITD; Peripheral blood stem cell transplantation; Preemptive donor lymphocyte infusions
Categories
Ask authors/readers for more resources
Patients with acute myeloid leukemia (AML) co-expressing NUP98/NSD1 and FLT3/ITD have a dismal prognosis despite undergoing hematopoietic stem cell transplantation (HSCT). There are a few studies on successful treatment of relapsed AML co-expressing NUP98/NSD1 and FLT3/ITD. We report a refractory case of molecular relapse of AML co-expressing NUP98/NSD1 and FLT3/ITD post-matched sibling HSCT. Donor lymphocyte infusion (DLI) at an early stage of post-transplantation resulted in complete molecular remission for 29 months with durable chronic graft-versus-host disease. Our case suggests the clinical efficacy of preemptive DLI following minimal residual disease analysis for the treatment of refractory AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available